MacroPore Biosurgery Receives CE Mark Approval for Hydrosorb™ Boomerang® the First Minimally Invasive Resorbable Lumbar Interbody Fusion Device in Europe

San Diego, CA, July 1, 2004 - MacroPore Biosurgery, Inc. (Frankfurt: XMP) (Reuters: MACP.DE) (Bloomberg: XMP) today announced that it has received the CE Mark approval to market Hydrosorb™ Boomerang® for interbody fusion in Europe. HYDROSORB™ Boomerang® implants will be marketed in Europe for spinal fusion procedures when vertebral discs are damaged after trauma, disease or age-related degeneration. They are made from a polylactide (PLa) resorbable material that provides temporary support while healing takes place. The material then naturally resorbs into the body over time. The products will be manufactured by MacroPore Biosurgery and distributed throughout Europe by Medtronic Sofamor Danek.

"This is an important extension to our Hydrosorb™ line as it represents the very first resorbable, minimally invasive lumbar interbody fusion device in Europe," said Sharon Schulzki, Chief Operating Officer, MacroPore Biosurgery. "Traditional approaches to spine fusion surgery involve extensive surgical exposure and prolonged periods of retraction that can injure back muscles and lead to considerable post-surgical pain. To help minimize these issues, minimal access surgical techniques have been developed. The availability of HYDROSORB™ Boomerang® for use in minimal access insertion techniques enables the surgeon to combine the benefits of a resorbable interbody device with the advantages of existing minimal access technology."

About MacroPore Biosurgery, Inc.

MacroPore Biosurgery (Frankfurt: XMP) is focused on the discovery, development and commercialization of regenerative medicine technologies. We have two technology platforms, bioresorbable technology and regenerative cell technology. Our surgical implants, derived from our bioresorbable technology, represent one of the latest advancements in spine and orthopedic medicine. They are manufactured by us and distributed exclusively through Medtronic Sofamor Danek. Within our regenerative cell technology program, we are developing a system to isolate autologous, homologous-use, regenerative cells. Simultaneously, we are generating scientific knowledge through internal research to support the clinical use of these cells. Our most advanced research and development program is in the repair of cardiovascular tissues that are damaged after a heart attack. We are also researching applications in bone repair, spinal disc regeneration, and cosmetic and reconstructive surgery. For further information please visit our web site [http://www.macropore.com](http://www.macropore.com).

Cautionary Statement Regarding Forward-Looking Statements

This press release may include forward-looking statements regarding events and trends which may affect MacroPore Biosurgery's future operating results and financial position. Such statements are subject to risks and uncertainties that could cause MacroPore Biosurgery's actual results and financial position to differ materially. These risks and uncertainties are described (under the heading "Risk Factors") in our 2003 Form 10-K annual report for the year ended December 31, 2003, which is available on our web site. MacroPore Biosurgery assumes no responsibility to publicly release the results of any revision of forward-looking statements to reflect events, trends or circumstances after the date they are made.